Active, not recruitingNot applicableNCT03389347
High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
Studying Plasma cell leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Washington
- Principal Investigator
- Danai Dima, MDFred Hutch/University of Washington Cancer Consortium
- Intervention
- Biospecimen Collection(procedure)
- Enrollment
- 40 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2026
Study locations (1)
- Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03389347 on ClinicalTrials.govOther trials for Plasma cell leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07509086IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell LeukemiaThe First Hospital of Jilin University
- RECRUITINGPHASE2NCT06517017Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple MyelomaUniversity of Utah
- RECRUITINGPHASE2NCT07106684ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell LeukemiaInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGEARLY PHASE1NCT06730256A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell LeukemiaThe First Affiliated Hospital of Soochow University
- RECRUITINGNANCT07052916A Music Therapy Study for Blood Cancer Survivors With Cognitive DifficultiesMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE2, PHASE3NCT07202091Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig)Monash University
- RECRUITINGEARLY PHASE1NCT06718270a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell LeukemiaShanghai Changzheng Hospital
- RECRUITINGPHASE2NCT06140966Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple MyelomaUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology